Aktis Oncology, Inc. (AKTS)
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Aktis Oncology, Inc.
- 1.1:1Forward splitApr 24, 20151 share → 1.1
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Revenue | $6.5M | $1.49M | $0 | $0 |
| YoY Growth | 336.9% | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $6.5M | $1.49M | $0 | $0 |
| Gross Margin | 100.0% | 100.0% | - | - |
| Research and Development | $67.45M | $40.95M | $25.92M | $14.3M |
| Selling, General, and Administrative | $12.6M | $11.31M | $7.68M | $5.11M |
| Other | $1.13M | $1.28M | $1.2M | $356K |
| Total Operating Expenses | $81.18M | $53.54M | $34.79M | $19.76M |
| Operating Income (EBIT) | -$74.68M | -$52.05M | -$34.79M | -$19.76M |
| Operating Margin | -1149.5% | -3500.3% | - | - |
| Interest Expense | $0 | $0 | $0 | $0 |
| Interest Income | $11.01M | $8.1M | $5.38M | $1.65M |
| Other Income (Expense) | $10.95M | $8.07M | $6.15M | $1.83M |
| Income Before Tax (EBT) | -$63.73M | -$43.98M | -$28.64M | -$17.93M |
| Income Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$63.73M | -$43.98M | -$28.64M | -$17.93M |
| Net Income Margin | -980.9% | -2957.6% | - | - |
| Supplementary Data | ||||
| EPS | -1.19 | -1.26 | -0.82 | -0.51 |
| Diluted EPS | -1.19 | -1.26 | -0.82 | -0.51 |
| Weighted Average OS | 52.52M | 34.86M | 34.86M | 34.86M |
| EBITDA | -$61.4M | -$42.41M | -$27.52M | -$17.48M |
| EBITDA Margin | -945.1% | -2851.7% | - | - |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Assets | ||||
| Current Assets | ||||
| Cash and Cash Equivalents | $37.78M | $37.16M | $29.51M | $128.6M |
| Short-Term Investments | $189M | $260.01M | $68.35M | $0 |
| Cash and Short-Term Investments | $226.79M | $297.17M | $97.86M | $128.6M |
| Accounts Receivable | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Current Assets | $3.52M | $3.69M | $2.34M | $3.88M |
| Total Current Assets | $230.31M | $300.85M | $100.2M | $132.48M |
| Long-Term Assets | ||||
| Property, Plant & Equipment Net | $27.25M | $20.87M | $20.92M | $4.87M |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $7.33M | $4.46M | $1.23M | $976K |
| Total Long-Term Assets | $34.58M | $25.33M | $22.15M | $5.84M |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $264.88M | $326.18M | $122.36M | $138.32M |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payable | $1.74M | $1.92M | $957K | $490K |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $18.66M | $9.28M | $0 | $0 |
| Other Current Liabilities | $4.56M | $3.08M | $2.03M | $1.19M |
| Total Current Liabilities | $31.24M | $18.82M | $6.24M | $5.28M |
| Long-Term Liabilities | ||||
| Long-Term Debt | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $36.16M | $51.04M | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $333.41M | $333.41M | $150.55M | $151.36M |
| Total Long-Term Liabilities | $379.8M | $395.16M | $162.42M | $152.28M |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Total Liabilities | $411.03M | $413.98M | $168.66M | $157.55M |
| Stockholders' Equity | ||||
| Preferred Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$156.56M | -$92.83M | -$48.85M | -$20.21M |
| Comprehensive Income & Other | $42K | $124K | $82K | $0 |
| Other Stockholders' Equity | $10.41M | $5.03M | $2.55M | $982K |
| Total Equity | -$146.15M | -$87.8M | -$46.31M | -$19.23M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $264.88M | $326.18M | $122.36M | $138.32M |
| Supplementary Data | ||||
| Total Debt | $11.55M | $12.01M | $13.4M | $1.77M |
| Net Debt | -$26.24M | -$25.15M | -$16.11M | -$126.82M |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Operating Activities | ||||
| Net Income | -$63.73M | -$43.98M | -$28.64M | -$17.93M |
| Depreciation & Amortization | $2.33M | $1.57M | $1.12M | $445K |
| Deferred Income Tax | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $5.13M | $2.26M | $1.48M | $698K |
| Changes in Working Capital: | ||||
| Accounts Receivable | $1.03M | -$861K | -$257K | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Accounts Payable | -$44K | $360K | $659K | -$1K |
| Other Working Capital | -$4.22M | $59.48M | -$417K | -$1.14M |
| Total Working Capital Change | -$3.23M | $58.98M | -$15K | -$1.14M |
| Other Non-Cash Items | -$4.62M | -$4.07M | -$3.95M | -$200K |
| Net Cash from Operating | -$64.13M | $14.76M | -$30M | -$18.13M |
| Investing Activities | ||||
| Capital Expenditures | -$9.58M | -$2.86M | -$3.76M | -$2.31M |
| Acquisitions | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$193.87M | -$288.4M | -$145.81M | $0 |
| Sales of Investments | $269.42M | $100.86M | $80.69M | $0 |
| Other Investing Activities | $0 | $0 | $57K | $0 |
| Net Cash from Investing | $65.96M | -$190.4M | -$68.83M | -$2.31M |
| Financing Activities | ||||
| Debt Repaid | - | - | - | - |
| Common Stock Issuance | $336K | $0 | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$1.55M | -$1.72M | $0 | -$151K |
| Net Cash from Financing | -$1.21M | $183.28M | $0 | $119.98M |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $625K | $7.65M | -$98.83M | $99.55M |
| Supplementary Data | ||||
| Operating Cash Flow | -$64.13M | $14.76M | -$30M | -$18.13M |
| Capital Expenditure | -$9.58M | -$2.86M | -$3.76M | -$2.31M |
| Free Cash Flow | -$73.71M | $11.9M | -$33.77M | -$20.43M |
| Cash at Beginning | $38.31M | $30.66M | $129.49M | $29.94M |
| Cash at End | $38.93M | $38.31M | $30.66M | $129.49M |